| Name | Vps34-IN-2 |
| Description | Vps34-IN-2 is a potent and selective Vps34 inhibitor (IC50s: 2 and 82 nM on the Vps34 enzymatic assay and the GFP-FYVE cellular assay, respectively). |
| In vitro | Vps34-IN-2 displays IC50s of 2 and 82 nM on the Vps34 enzymatic assay and the GFP-FYVE cellular assay, respectively. Vps34-IN-2 exhibits selectivity against mTOR with IC50 more than 10 μM and class I PI3Ks with IC50 values of 2.7, 4.5, 2.5, and >10 μM on PI3K α, β, δ, γ isoforms, respectively. |
| In vivo | After oral administration (po), Vps34-IN-2 is rapidly absorbed with maximal plasma concentrations observed at 0.5 h and a bioavailability of 85%. Slight rebounds of concentrations are observed at 4 and 8 h after oral dosing with no obvious explanation. After iv injection of Vps34-IN-2 at 3 mg/kg, plasma clearance is found moderate (i.e., 2.3 L/h/kg), corresponding to 44% of hepatic blood flow in this species, volume of distribution at steady state is moderate, and terminal elimination half-life is short. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 50 mg/mL (124.25 mM), Sonication is recommended.
|
| Keywords | Vps34-IN-2 | Vps-34-IN-2 | Vps34IN2 | Vps34 IN 2 | Vps34 |
| Inhibitors Related | Myricetin | Erucic acid | Sapanisertib | (2S,3R,4S)-4-Hydroxyisoleucine | 3-Methyladenine | Duvelisib (R enantiomer) hydrochloride | RLY-2608 | Isoprenaline hydrochloride | Quercetin Dihydrate | Apilimod | LY294002 | Idelalisib |
United States
